drugset / Trial / NCT05300035
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
Phase 2
Recruiting
69 enrolled
ANRS, Emerging Infectious Diseases
Institut Pasteur · collabRockefeller University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.
Timeline
- Start
- 2024-04-11
- Primary completion
- 2026-12-10
- Completion
- 2028-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Teropavimab | Monoclonal antibody | — | Intravenous |
| Comparator | Zinlirvimab | Monoclonal antibody | — | Intravenous |